Claims
- 1. A capsule device for delivery of a beneficial agent to an aqueous environment comprising:
- a. a beneficial agent, said beneficial agent is poorly soluble in the aqueous environment and is a pharmaceutical or veterinary agent;
- b. an osmagent;
- c. a macroparticulate solubility modifier that is selected to modify the solubility of the beneficial agent and thus provides a predetermined beneficial agent solubility and wherein said macroparticulate solubility modifier comprises compressed macroparticles and wherein said device includes uncoated solubility modifier;
- d. said macroparticulate solubility modifier having a coating thereon, said coating peaceable to the aqueous environments, wherein said macroparticulate coating is a mixture of cellulose acetate and polyethyleneglycol and said coated macroparticulate solubility modifier being 0.16 cm to 1.27 cm in diameter wherein said macroparticulate contains a mixture of N-methyl glucamine and hydroxypropylcellulose; and
- e. an asymmetric membrane surrounding said beneficial agent, osmagent and macroparticulate solubility modifier wherein the device does not include a hydrogel and the coated macroparticulate solubility modifier does not include the beneficial agent.
- 2. The device as recited in claim 1 wherein said solubility modifier is an osmagent.
- 3. The device as recited in claim 1 wherein said solubility modifier is the osmagent.
- 4. The device as recited in claim 1 wherein said beneficial agent is the osmagent.
- 5. The device as recited in claim 1 wherein said macroparticulate coating has a duration sufficient to achieve release of substantially all the beneficial agent.
- 6. The device as recited in claim 1 wherein said device includes two macroparticulates, said macroparticulates having substantially different release time lags.
- 7. A method for the delivery of a beneficial agent to an aqueous environment of use which comprises placing the device of claim 1 into the aqueous environment of use.
- 8. The device as recited in claim 1 wherein said beneficial agent is highly soluble in the aqueous environment.
BACKGROUND OF THE INVENTION
This application was filed under 35 U.S.C. .sctn.371 based on PCT/US93/09582, which was filed on Oct. 13, 1993 which is a continuation of U.S. application Ser. No. 07/979,727 which was filed on Nov. 20, 1992 and is now abandoned.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US93/09582 |
10/13/1993 |
|
|
5/11/1995 |
5/11/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO94/12152 |
6/9/1994 |
|
|
US Referenced Citations (7)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0357369 |
Mar 1990 |
EPX |
Non-Patent Literature Citations (1)
Entry |
G. A. McClelland et al, "The Solubility-Modulated Osmotic Pump: In vitro/In vivo Release of Diltiazem Hydrochloride", Pharma. Research, vol. 8, No. 1, pp. 88-92 (1991). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
979727 |
Nov 1992 |
|